Premium Nahrungsergänzungsmittel | artgerecht

Bimekizumab – Uses, Mechanism & Side Effects

Bimekizumab is a biologic medication used to treat psoriasis and other inflammatory conditions. It selectively blocks both IL-17A and IL-17F to reduce inflammation.

Regular tips about health Regular tips about health

Things worth knowing about "Bimekizumab"

Bimekizumab is a biologic medication used to treat psoriasis and other inflammatory conditions. It selectively blocks both IL-17A and IL-17F to reduce inflammation.

What is Bimekizumab?

Bimekizumab is a monoclonal antibody belonging to the class of biologic medicines. It was developed to specifically target and suppress certain inflammatory processes in the body. The drug is marketed under the brand name Bimzelx and has received approval from the European Medicines Agency (EMA) as well as other regulatory authorities.

Indications

Bimekizumab is approved for the treatment of the following conditions in adults:

Moderate to severe plaque psoriasis when other treatments have been inadequate or not tolerated
Active psoriatic arthritis (joint inflammation associated with psoriasis)
Ankylosing spondylitis (Bechterew disease) and non-radiographic axial spondyloarthritis
Hidradenitis suppurativa (acne inversa), a chronic skin condition

Mechanism of Action

Bimekizumab is a dual IL-17A and IL-17F inhibitor. This means it simultaneously blocks two key signalling proteins of the immune system: interleukin-17A (IL-17A) and interleukin-17F (IL-17F).

Both of these interleukins play a central role in driving the inflammatory responses characteristic of diseases such as plaque psoriasis and spondyloarthritis. By blocking both proteins at once, bimekizumab can suppress inflammation more comprehensively than agents that target IL-17A alone.

Administration and Dosage

Bimekizumab is administered as a subcutaneous injection, meaning it is injected under the skin using a pre-filled pen or syringe. After appropriate training, patients can self-administer the injection at home.

The recommended dosage depends on the condition being treated:

Plaque psoriasis: 320 mg every 4 weeks during the induction phase, then every 8 weeks
Psoriatic arthritis and spondyloarthritis: 160 mg every 4 weeks
Hidradenitis suppurativa: 320 mg every 2 weeks during the induction phase, then every 4 weeks

Dosage should always be determined by the treating physician based on individual patient needs.

Side Effects

Like all biologic therapies, bimekizumab may cause side effects. The most commonly reported include:

Upper respiratory tract infections (e.g., runny nose, sore throat)
Oral candidiasis (fungal infections in the mouth and throat) – a characteristic effect of IL-17 inhibition
Injection site reactions
Headache
Elevated liver enzyme levels

Less common but serious side effects include severe infections and possible worsening of inflammatory bowel diseases such as Crohn's disease.

Contraindications and Precautions

Bimekizumab should not be used in patients with:

Active, serious infections (e.g., active tuberculosis)
Known hypersensitivity to the active substance or any of the excipients

A tuberculosis screening is recommended before initiating treatment. Patients with a history of inflammatory bowel disease should be monitored closely. Use during pregnancy and breastfeeding should only be considered after careful assessment of benefits and risks by the treating physician.

Treatment Context

Bimekizumab is typically prescribed when conventional therapies (e.g., methotrexate, ciclosporin) or other biologics (e.g., TNF inhibitors) have proven insufficient or poorly tolerated. It belongs to the modern class of targeted immunotherapies and represents an effective treatment option for many patients with difficult-to-treat psoriasis or spondyloarthritis.

References

European Medicines Agency (EMA): Bimzelx (bimekizumab) – Summary of Product Characteristics. Available at: https://www.ema.europa.eu (accessed 2024)
Gordon KB et al. – Bimekizumab versus Secukinumab in Plaque Psoriasis. New England Journal of Medicine, 2023.
Deodhar A et al. – Bimekizumab in Patients with Active Ankylosing Spondylitis. The Lancet, 2021.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.